Medical Species Used in Russia for the Management of Diabetes and Related Disorders

Background: Polyherbal mixtures called “medical species” are part of traditional and officinal medicine in Russia. This review aimed to analyze medical species used in Russia for the treatment of diabetes and related disorders. The information relevant to medical species, diabetes, and obesity was collected from local libraries, the online service E-library.ru, and Google Scholar. The prediction of the antidiabetic activity for the principal compounds identified in plants was performed using the free web resource PASS Online. Results: We collected and analyzed information about the compositions, specificities of use, and posology of 227 medical species. The medical species represent mixtures of 2–15 plants, while the most frequently mentioned in the literature are species comprising 3–6 plants. The top 10 plants among the 158 mentioned in the literature include Vaccinium myrtillus L., Phaseolus vulgaris L., Taraxacum campylodes G.E. Haglund., Urtica dioica L., Rosa spp., Hypericum spp., Galega officinalis L., Mentha × piperita L., Arctium spp, and Fragaria vesca L. The leading binary combination found in medical species comprises the leaves of V. myrtillus and pericarp of P. vulgaris; leaves of V. myrtillus and leaves of U. dioica; and leaves of V. myrtillus and aerial parts of G. officinalis. In triple combinations, in addition to the above-mentioned components, the roots of T. campylodes are often used. These combinations can be regarded as basic mixtures. Other plants are added to improve the efficacy, treat associated disorders, improve gastrointestinal function, prevent allergic reactions, etc. Meanwhile, an increase in plants in the mixture necessitates advanced techniques for quality control. A feature of medical species in Russia is the addition of fresh juices, birch sap, seaweeds, and adaptogenic plants. Modern studies of the mechanisms of action and predicted activities of the principal compounds from medicinal plants support the rationality of polyherbal mixtures. Nevertheless, the mechanisms are not well studied and reported due to the limited number of compounds. Further investigations with calculations of synergistic or additive indices are important for strengthening the scientific fundamentals for the wider use of medical species in the therapy of diabetes. Two medical species, “Arfazetin” (7 medicinal plants) and “Myrphasinum” (12 medicinal plants), are approved for use in officinal medicine. The efficacy of these species was confirmed in several in vivo experiments and clinical trials. According to modern regulatory rules, additional experiments and clinical trials are required for more detailed investigations of the mechanisms of action and confirmation of efficacy. Conclusion: We believe that the scientifically based utilization of rich plant resources and knowledge of Russian herbal medicine can significantly contribute to the local economy as well as to the sectors seeking natural healing products.


INTRODUCTION
Disorders of carbohydrate and lipid metabolism predispose individuals to diseases of the endocrine system, particularly diabetes. The rapid increase in patients with diabetes is one of the gravest and fastest-growing public health problems in the world. About 463 million people currently suffer from diabetes globally (IDF, 2019), of whom over 60 million were in European countries (Timmis et al., 2020), 34.2 million in the US (Centers for Disease Control and Prevention, 2020), and 4.5 million in Russia in 2017 (Dedov et al., 2018).
The mean cost of the development of a new drug from concept to market is considered to range from $314 million to $2.8 billion (Wouters et al., 2020). According to recent literature data, 50-70% of all the small-molecule therapeutics in clinical use today trace their origins to natural products (Newman and Cragg, 2020). Medicines derived from natural sources exhibit greater ranges of structural and physicochemical features that have been tailored through evolution for selective binding to functional macromolecules of the human body (Stratton et al., 2015). The intensive exploration of natural resources and utilization of the knowledge of traditional medicine provides an opportunity to reduce the time needed for development and keep costs reasonably low.
About four billion people around the world believe that, as "natural" products, herbal medicinal products (HMP) are "safe" or "safer" than conventional drugs and have turned to phytotherapeutics (Ekor, 2014). For centuries, Russia has been regarded a "herbophilious" society in which plants have been used as one of the primary foods and for the treatment of different diseases (Shikov et al., 2017). It is estimated that 58-60% of the population of Russia relies on HMP for the prophylaxis or treatment of different diseases (Shikov et al., 2011;Sammons et al., 2016). HMP currently makes up 20% of the Russian market for drugs (Akamova et al., 2017).
Medicinal plants have been effectively used for the treatment of diabetes in different systems of traditional as well as officinal medicine (Anzar, 2013;Shikov et al., 2014;Suzuki et al., 2017;Xiao and Luo, 2018;Okovitiy et al., 2018;Skalli et al., 2019;Salehi et al., 2019). The philosophy "one disease, one target, one drug" oversimplifies the mechanisms of disease and is becoming increasingly inefficient (Ulrich-Merzenich, 2014;Panossian et al., 2018;Shikov et al., 2018). Due to its multifactorial etiology, the holistic treatment of diabetes requires multipathway understanding and multi-targeting approaches.
Multicomponent or polyherbal mixtures for the treatment of diabetes are presented in different systems of Eastern traditional medicine (Namdul et al., 2001;Sato, 2004;Tong et al., 2012;Malgaonkar et al., 2016;Ghadge and Kuvalekar, 2017;Suzuki et al., 2017;Xu et al., 2019) as well as in European herbal medicine (Madić et al., 2021). Such traditional formulations include carefully selected leaves, stems, flowers, roots, seeds, sometimes minerals, and animal products. The main goal of complicated mixtures is to increase therapeutic efficacy and minimize toxicity.
Russian herbal medicine has adopted Eastern philosophy and a Western pragmatic approach. Herbal medicine in Russia is part of officinal medicine. According to the 14th edition of the State Pharmacopoeia of the Russian Federation, which became effective in 2018, an HMP has been defined as "a medicinal product manufactured or prepared from one kind of medicinal plant material or several kinds of raw materials and marketed in consumer-ready packaging form" (The State Pharmacopoeia of Russian Federation, 2018). The general monograph (OFS.1.4.1.0020.15) is devoted to polyherbal mixtures, which are defined with the specific term "medical species". A "medical species" is a formulation representing a mixture of two or more types of integral, cut, or powdered medicinal plant materials, sometimes with the addition of mineral, synthetic, plant, or animal-derived substances. Medical species are used for the preparation of aqueous decoctions/infusions, occasionally in pure form as powders, powders for insufflation or ingestion, etc. (The State Pharmacopoeia of Russian Federation, 2018). Medical species have been known in Russia for centuries and were documented in the first herbalist manuscripts (Zmeev, 1896;Shikov et al., 2021). Apparently, due to their efficacy, the medical species were adopted from traditional medicine in officinal and were monographed in the first Russian military field "Pharmacopoeia Castrensis Rossica., 1765". Thereafter, medical species were embodied in all the following pharmacopoeias of Russia.
The polyherbal mixtures used in Eastern systems of traditional medicine have gained global popularity, and several new medicinal products are being marketed in different countries. However, the potential of the medical species used in Russia remains little known and underestimated. This review aimed to analyze the medical species used in Russia for the treatment of diabetes and related disorders and enable a better understanding of the rationality of plant combinations.
Information on medical species was collected from the Pharmacopoeias of Russia (I-VI editions), Pharmacopoeias of USSR (VII-XI editions), and online State Register of Medicinal Preparations of the Russian Federation (2021). Guided by the keywords "traditional medicine + diabetes", "phytotherapy + diabetes", "traditional medicine + obesity", and "phytotherapy + obesity", we systematically searched the literature in library catalogs, on the online service E-library.ru, and on Google Scholar. Next, the publications were screened using the keyword combination "medical species". Through this approach, 75 medical (herbalist) books were found. Some medical species were mentioned in different books. We provide several references for the same medical species in Table 1.

RESULTS AND DISCUSSION
For centuries, medicinal plants have been used in Russia for the management of diabetes and related disorders (Zmeev, 1896;Turova and Sapozhnikova, 1989;Minaeva, 1991;Protasenya and Vasilenko, 1992;Nazina, 2007;Chekina et al., 2010;Korsun et al., 2016;Povydysh et al., 2018). The focus of the current paper is on medical species used for the therapy of diabetes and related diseases in traditional and officinal Russian medicine.

The Characteristics of the Composition of Medical Species, Their Preparation and Posology
We collected information about the composition, specificity of preparation, and posology of 227 species ( Table 1). The majority of the species (148) are suggested for the treatment of diabetes; 37 species are recommended for the management of obesity, and eight species are indicated for lowering blood glucose. Several species are recommended for specific cases when diabetes is accompanied by impotence in men (5 species), diabetes accompanied by liver and gallbladder diseases (3 species), diabetes accompanied by gastritis (2 species), etc. Altogether, 158 plants are mentioned in medical species, among which 96 medicinal plants are monographed in the State Pharmacopoeia of the Russian Federation and used in officinal medicine . A significant proportion of the plants used in medical species are native to Russian flora.
Medical species represent mixtures of 2-15 plants. The most frequently mentioned in the literature are medical species comprising mixtures of four plants (66 species), followed by mixtures of five plants (47 species), three plants (28 species), and six plants (24 species) ( Figure 1). According to some experts' opinions, the industrial-scale production of polyherbal mixtures with more than 10 medicinal plants is not rational (Kiseleva and Chauzova, 1999). Indeed, only 18 species among the 227 described contain over 10 plants (Figure 1). However, the numbers of plants in polyherbal mixtures in Ayurveda (Parasuraman et al., 2014), Kampo (Arai et al., 2020), and traditional Chinese medicine (Xutian et al., 2014) are not limited to 10. On the other hand, the species "Myrphasinum", approved as officinal medicine in Russia, includes 12 plants ( Table 1). Although the idea of combining so many plants in one mixture is part of traditional medicine, the quality control of medical species becomes more complicated with each additional component due to challenges related to the specificity of each plant.
Medical species are prepared predominantly in form of infusions or decoctions. Infusions are common for soft plant parts such as aerial parts, leaves, and flowers. Decoctions are preferred for more hard barks, fruits, and roots. The recommended single doses vary from a tablespoon up to 200 ml and depend on the pharmacological activity of the plants in the mixture.

The Plants Most Frequently Used in Medical Species
The top 10 plants in medical species used for the therapy of diabetes and related disorders ( Table 1)  Particularly, aerial parts, fruits, and roots (Petroselinum crispum (Mill.) Fuss); leaves, flowers, and roots (Sambucus nigra L.); and roots and leaves (Cichorium intybus L., Rubus caesius L., and Arctium spp.) have been used.

The Popular Combinations of Medicinal Plants and Rationality for Combination
It is believed that, in medical species, several herbs work together harmoniously to achieve an ideal therapeutic effect. Modern studies on the mechanisms of activities of individual plant extracts support the rationality of empirically composed polyherbal mixtures in traditional medicine. Furthermore, we discuss the most frequent combinations of plants used in medical species in light of their mechanisms of action. The most frequently mentioned binary combinations of plants in medical species used for the treatment of diabetes are specified in Table 2.
Notably, the binary combinations of the leaves of Vaccinium myrtillus L. and pericarp of Phaseolus vulgaris L.; leaves of Vaccinium myrtillus L. and roots of Arctium spp.; and roots of Taraxacum campylodes G.E. Haglund. and leaves of Mentha × piperita L. occur as self-sufficient medical species (Table 1).
Deeper analysis of all the medical species allowed us to identify leading ternary plant combinations, which are presented in Figure 2. It is not surprising that

In Silico Probability of Antidiabetic Activity for Principal Compounds Identified in Selected Plants
The progress in computer science in symbiosis with modern pharmacology has led to the active implementation of computerbased prognosis for the activity of herb-derived compounds.
Using an in silico approach, we analyzed the probability of antidiabetic activity for the principal compounds identified in the plants most often mentioned in binary and ternary combinations.
The prediction was performed using the free web resource PASS Online (Prediction of Activity Spectra for Substances). The prediction is based on an analysis of the structure and biological activity relationships for more than 300,000 organic compounds (Filimonov et al., 2014). Table 4 includes the prediction results for the antidiabetic efficacy of active compounds from selected medicinal plants with appropriate probability values: the likelihood of the given activity being revealed (Pa) or not revealed (Pi). If Pa>0.5, the substance is very likely to exhibit the activity (Lagunin et al., 2000).
The predicted Pa values for the active compounds identified in the most frequently used combinations of plants in medical species were over 0.5 and ranged from 0.619 for compounds from Fragaria vesca L. up to 0.976 for compounds from Hypericum perforatum L. ( Table 4). The highest Pa values were found for compounds derived from Urtica dioica L., Hypericum perforatum L., Vaccinium myrtillus L., Fragaria vesca L., Linum usitatissimum L., and Vaccinium vitis-idaea L. (Pa>0.9). The diagram in Figure 3 demonstrates crosslinks between medicinal plants with a high probability of predicted antidiabetic effects (Table 4) used in medical species. The calculated data support the rationality of the traditional use of medical species for the treatment of diabetes and its complications. Nevertheless, the chemical principles responsible for the observed effects are rarely studied. Except for the success story of metformin derived from Galega officinalis L., no other compounds are on the market. Systematic studies of the combinatory action of different plant decoctions/infusions, as well as plant-derived compounds, are needed.

Specificity of Medical Species Used in Russia
Several plants used in Russian traditional medicines for the treatment of diabetes and its complications are widely known in other countries. The leaves of Urtica dioica L., pericarp of Phaseolus vulgaris L., leaves of Vaccinium myrtillus L., and leaves and roots of Taraxacum campylodes G.E. Haglund. are among the most frequently used components for the management of diabetes by herbalists in Croatia (Končić and Bljajić, 2019). Phaseolus vulgaris is a well-known antidiabetic plant in the Ayurveda and Unani medicine systems (Ganesan and Xu, 2017). It is widely used in medicine in Poland (Łabuda et al., 2017). The antidiabetic potential of Urtica dioica is well documented in Arabic traditional medicine (Said et al., 2008). Galega officinalis L. has been used for the treatment of diabetes in Bulgaria (Petkov, 1982), Italy (Leporatti andIvancheva, 2003), andIran (Nowbandegani et al., 2015).
Unlike in other systems of medicine, the juices of some plants (the berries of Viburnum opulus L., Solanum tuberosum L., and Daucus sativus Roehl. and birch sap) have been used for preparing some medical species. Interestingly, eleven medical species contain seaweeds (Cystoseira barbata (Stackh.) C. Agardh; Saccharina latissima (L.) C.E.Lane, C.Mayes, Druehl & G.W.Saunders; Fucus vesiculosus L.), and one species contains lichen (Cetraria islandica L.). It is noteworthy that several adaptogenic plants have been used in medical species. Besides the common properties of promoting the adaptability, resilience, and survival of living organisms under stress (Panossian et al., 2021), each adaptogen has some specific activity. In particular, Oplopanax elatus (Nakai) Nakai lowered blood glucose and increased insulin levels in vivo (Molokovskii et al., 2002). Glucose-and cholesterol-lowering effects, decreased glycosuria, and increased insulin levels were observed in diabetic patients after complex therapy with Oplopanax elatus (Nakai) Nakai (Klimakova and Kazmanm, 1962). Aralia elata (Miq.) Seem decreases blood glucose, inhibits insulin resistance, alleviates hyperlipidemia in vivo (Hwang et al., 2015), and improves blood glucose and lipid metabolism in humans (Abidov et al., 2006). The activity could be associated with aralosides (Pa, 0.639-0.969, Table 4). Eleutherococcus senticosus (Rupr. et Maxim.) Maxim. and its active compounds lowered blood glucose, increased glycogen levels, ameliorated insulin resistance, and increased insulin levels in vivo (Molokovskii et al., 2002;Niu et al., 2008;Ahn et al., 2013). The activity is associated with syringing and eleutheroside E (Pa, 0.684 and 0.887; Table 4). These adaptogens are not only used in medical species in traditional medicine but are included in the officinal medical species "Arfazetin" ( Table 1).

Principles for Compilation of Medical Species
Due to the specific location of Russia, Russian herbal medicine has adopted the philosophy of Eastern traditional medicine and the pragmatic approach of Western medicine. One of the main principles for the compilation of the formulas used in traditional Chinese medicine is described in Shen-nong Ben-Cao Jing. An effective formula should be based on a strong monarch, accompanied by a minister, assistant, and guide, which mimics a well-organized society (Xin et al., 2014;Xutian et al., 2014). However, this principle is difficult to follow in practice, due to the multiple symptoms of diseases and polyfunctionality of medicinal plants. Therefore, many formulas of TCM contain secrets that are not always explained by rationality (Wang et al., 2021).
The philosophy and conceptualization for the compilation of medical species in Russian medicine are not well described. After a comprehensive medical examination of a patient, a Russian phytotherapeutic doctor initially prescribes a basic medical species, which includes the plants that lower blood glucose. The binary and triple combinations emphasized in this review can be regarded as basic mixtures. Diabetes is often accompanied by obesity. Therefore, the basic mixture is fortified with plants reducing hypercholesterolemia. In the case of hypertension, the  Table 4.
Frontiers in Pharmacology | www.frontiersin.org July 2021 | Volume 12 | Article 697411 species include anti-hypertensive plants. The practical doctors also take into account the peculiarities of the gastrointestinal tracts of the patients. In this respect, medical species can include plants with astringent or laxative properties. To prevent allergic reactions, doctors recommend taking a basic mixture for a week and then continuously increasing the number of plants in the medical species one by one. Plants with antiallergic properties are sometimes included in the mixtures (Kovaleva, 1972;Ladynina and Morozova, 1987;Ladynina and Morozova, 1990). This approach could be illustrated by the following medical species frequently cited in the literature. The species 4.39 (Table 1) includes a synergistic combination of Vaccinium myrtillus L. and Galega officinalis L., which effectively decreases glucose levels (Achilov, 2020;Kurylo et al., 2020). These basic plants have antidiabetic properties. Frangula alnus Mill. acts as a laxative, and Betula pendula Roth. acts as a diuretic (Belodubrovskaya et al., 2004). Another species, 4.40 (Table 1), besides the synergistic combination of Vaccinium myrtillus L. and Galega officinalis L., includes Phaseolus vulgaris L., which reduces plasma triacylglycerol and low-density lipoprotein, and lowers blood glucose and cholesterol (Pari and Venkateswaran, 2004;Sidorova et al., 2017;Micheli et al., 2019). These basic plants ensure the antidiabetic effect, while Mentha × piperita L. additionally provides anti-hypertensive, antiallergic, and spasmolytic effects (Mahendran and Rahman, 2020). The species 5.10 ( Table 1) comprises 5 plants. The power of the basic mixture of the synergistic combination of Vaccinium myrtillus L. and Galega officinalis L. and Phaseolus vulgaris L. is reinforced by Taraxacum campylodes G.E. Haglund., which inhibits adipogenesis and fat accumulation (García-Carrasco et al., 2015). Additionally, Urtica dioica L. potentiates the activity of insulin and enhances the utilization of glucose (El Haouari and Rosado, 2019). We understand that the interpretation of the rationality of the above-mentioned medical species compilation took into account the results of modern research. Apparently, the architects of the discussed medical species compiled them according to their own experience and knowledge. Similar to the TCM formulas, some Russian medical species also have secrets that are yet to be deciphered. Nevertheless, the knowledge and practical experience of Russian traditional medicine were successfully utilized for the development of medical species used in officinal medicine.

Medical Species Used in Russian Officinal Medicine
In Russia, medical species are part of officinal medicine. Although medical species are available as OTC products, consultations with phytotherapeutic doctors are helpful and will lead to more effective results. Among the 227 medical species discussed in this review, only two, "Arfazetin" and "Myrphasinum", are approved for use in officinal medicine. Both species are recommended in the mild form of diabetes. The medical species "Arfazetin" was developed in the All-Union Institute of Medicinal and Aromatic Plants and was approved for medicinal use in 1986 (Ferubko et al., 2016). "Arfazetin" comprises seven medicinal plants (Table 1). In 1992, the composition of species was revised. The roots of Aralia elata (Miq.) Seem (syn. Aralia mandshurica Rupr. et Maxim.) or roots and rhizomes of Oplopanax elatus (Nakai) Nakai were excluded. Instead of these plants, the roots and rhizomes of Eleutherococcus senticosus (Rupr. et Maxim.) Maxim. were included in species at the same rate. A new species was named "Arfazetin-E". Both these species ("Arfazetin" and "Arfazetin-E") are now included in the State register (2021).
"Myrphasinum" was developed in 1985 by scientists from the first Moscow medical institute, named after I.M. Sechenov (Fas'kov et al., 1991), and was approved for medicinal use in 1991. The composition is complicated and includes the 12 medicinal plants ( Table 1).
According to the regulatory requirements of the USSR/Russia, medical species are subject to preclinical and clinical evaluations of safety and efficacy.

Preclinical and Clinical Data
The efficacy of "Arfazetin" was studied in several experiments in vivo. Rats with alloxan-induced diabetes were administered an infusion of "Arfazetin" (10 ml/kg per day, orally) five days before alloxan injection and seven days after injection. Distilled water was administered in the control group. The blood glucose level, elevated by alloxan, was decreased in "the Arfazetin"-treated rats by 24 and 38% when compared with control on the third and seventh days, respectively, after alloxan injection. The total cholesterol, creatinine, and malondialdehyde in the blood and liver were decreased by 27, 37, 30, and 30%, respectively, compared with the control group on the seventh day after treatment. The treatment of rats with "Arfazetin" led to an increase in serum immunoreactive insulin and C-peptide after glucose load by 22 and 55%, respectively, when compared with the control group (Azhunova et al., 2001). Similar results were observed in a prolonged study. The oral administration of "Arfazetin" (5 ml/kg of infusion) to rats with alloxan-induced diabetes over 30 days (7 days before alloxan induction and 23 days after injection) resulted in decreases in blood glucose of 46 and 39%, respectively, compared with the control group on the 15th and 30th days of the experiment. On Day 30, glycogen in the liver was increased by 17% when compared with the control group (Ishankulova et al., 2013). A further study by the same group evidenced the lipid-lowering properties of "Arfazetin" (infusion, 5 ml/kg, orally). The total cholesterol in the blood decreased by 33% when compared with the negative control after 30 days of the treatment of rats with alloxan-induced diabetes. The levels of triglycerides and low-and high-density lipoproteins normalized and were equal to those in the intact group after 30 days of treatment with the infusion of "Arfazetin" (Ishankulova and Yuldasheva, 2019). In another study, the effects of "Arfazetin" on energy metabolism in rats were reported. Rats with alloxan-induced diabetes were treated with the infusion of "Arfazetin" (10 ml/kg, orally, daily) for 21 days. The control group received the same volume of distilled water. The treatment of rats with "Arfazetin" resulted in a double increase in adenosine triphosphate production in the liver when compared with control, starting from the seventh day of the experiment. The concentration of lactic acid decreased by 1.7 fold, while the activity of pyruvate kinase increased by 1.5 fold when compared with the control group after 21 days of treatment. The authors suggest positive effects of "Arfazetin" on energy metabolism (Lemza et al., 2014). The blood glucose in rats with alloxan-induced diabetes was decreased by 3.2 fold when compared with control at 3 h after the intragastric administration of a dry extract of the medical species "Arfazetin" (1,200 ng/kg). The efficacy of the extract was equal to that of gliclazide (50 mg/kg, intragastric administration) (Kvasova, 2011).
The acute and chronic toxicity of "Arfazetin" was studied in mice after oral administration. The LD 50 for the dry extract of "Arfazetin" was 24 g/kg (acute toxicity). No signs of toxicity were observed in the mice after 30 days of the administration of the "Arfazetin" infusion and dry extract at 1,200 mg/kg (there times a day every 4 h) (Kvasova et al., 2010).
The antidiabetic potential of the medical species "Myrphasinum" was investigated in rats. Diabetes was modulated by the subcutaneous injection of alloxan. The glucose level in the blood was increased from 5.6 mmol/L (intact group) to 9.55 mmol/L, body weights were decreased, and the rats had no appetite. The aqueous infusion of "Myrphasinum" (25 g/L) was administered to rats by an intragastric route at the dose of 5 ml/kg three times per day for two weeks. The control group was administered saline. The blood glucose in the treated group was decreased to 3.4 mol/L (vs. an increase up to 10.7 ml/L in the control group) two weeks after the beginning of treatment. The body weights and appetite were improved. Meanwhile, 25% of the animals in the control group died. The animals were observed for five extra weeks after the end of treatment with "Myrphasinum". Three weeks after the end of treatment, the blood glucose in the treated group was equal to that in the intact group (5.77 mmol/L) and was stable until the fifth week (Grinkevich et al., 1997). In another study, outbred rats with alloxan-induced diabetes were orally administered 10 ml/kg of an infusion of "Myrphasinum" 3 times a day for three weeks. The control group received the same dose of normal saline. The treatment with "Myrphasinum" resulted in a statistically significant decrease in blood glucose by 26% compared with control. Glycogen in the liver and skeletal muscles was increased by 35 and 21% respectively, when compared with control and was equal to the level in an intact group (Dzhafarova, 2013). Subsequently, the efficacy of "Myrphasinum" in outbred rats with alloxan-induced diabetes was evaluated. The rats were treated orally with 10 ml/kg of an infusion of ""Myrphasinum" 3 times a day. The control group received normal saline. Metformin (5 mg/kg, 2 times a day) served as a positive control. The administration of "Myrphasinum" for 21 days did not affect the body weights of the rats, and no signs of toxicity were observed. The level of glucose in the "Myrphasinum"-treated group was decreased by 75% compared with control (vs. 59% in the metformin group). The insulin and C-peptide levels were dramatically reduced by 3 and 3.3 fold, respectively, in rats after alloxan injection in those treated with "Myrphasinum" (vs. 1.5 and 1.7 fold increases, respectively, in the animals treated with metformin) (Jafarova and Garayev, 2013).
We have found, in the available literature, only a few publications about clinical trials with medical species. The efficacy of "Arfazetin" was studied in a group of 32 patients (18-65 years old) with types I and II diabetes mellitus. "Arfazetin" was prepared in the form of an aqueous infusion (10 g in 400 ml) and administered in warm form at the dose of 1/3 glass, three times a day, 30 min before meals, for one month. The patients with type I diabetes (12 persons) were administered "Arfazetin" in combination with an appropriate dose of insulin and diet. The five patients with a mild form of type II diabetes were administered "Arfazetin" in combination with an appropriate diet. The group of 15 patients with a moderate form of type II diabetes were administered "Arfazetin" in combination with an appropriate dose of hypoglycemic drugs and diet. In the patients with type I diabetes treated with "Arfazetin", a statistically significant decrease in blood glucose (by 38%) was registered at 11.00 pm when compared with 9.00 am of the same day. The effect was not cumulative. More pronounced results were observed in patients with type II diabetes. "Arfazetin" effectively ameliorated hyperglycemia. The doses of hypoglycemic drugs were reduced in 7 patients. In two patients, it was possible to maintain normal blood glucose levels without hypoglycemic drugs (Korotkova et al., 1988).
A "Myrphasinum" infusion was used in clinical praxis for the therapy of patients with and without diabetes decompensation. The treatment of patients with diabetes in the compensation stage resulted in statistically significant decreases in glucose by 15 and 44% in the blood and urine, respectively. Cholesterol and B-lipoproteins were decreased by 18 and 21%, respectively. The effects of "Myrphasinum" in patients with diabetes in the decompensation stage were less pronounced (Fas'kov et al., 1991). However, the data provided in the inventor's certificate are limited and lacking other details.
The comparative efficacy of "Arfazetin" and "Myrphasinum" was studied in 57 patients with diabetes (22-76 years old) in an open clinical trial. The first group (26 persons) was treated with "Arfazetin", while the second group (31 persons) received "Myrphasinum". Basic therapy includes oral hypoglycemic drugs. "Myrphasinum" was considered more effective and resulted in a statistically significant decrease in blood glucose, surpassing "Arfazetin" in efficacy (Firsova et al., 1990). However, no more details were provided in this conference paper.

CONCLUSION
In this review, we analyze the compositions and potential of medical species used in Russian traditional and officinal medicine for the treatment of diabetes and related diseases. Several species besides medicinal plants contain fresh juices from berries, birch sap, and seaweeds. Another aspect of medical species is the presence of adaptogens. The philosophy and conceptualization for the compilation of medical species in Russian medicine are not well described. We have highlighted the most common binary and triple combinations of plants exploited in medical species. These combinations can be considered base mixes. Other plants are added to the mixtures to improve the efficacy, treat associated disorders, improve gastrointestinal function, prevent allergic reactions, etc. Obviously, Russian phytotherapeutic doctors compile polyherbal mixtures according to their own experience and knowledge. Modern studies of the mechanisms of action and predicted activities of the principal compounds from medicinal plants support the rationality of polyherbal mixtures. However, the mechanisms are not well studied and reported due to the limited number of compounds. Deeper investigations including gene expression will enable a better understanding of molecular mechanisms and targets. Although a few studies have evidenced possible additive/synergistic effects of herbal mixtures, additional investigations with calculations of synergistic or additive indices will assist in providing a scientific foundation for the wider use of medical species for the therapy of diabetes. Even though most medical species comprise mixtures of three to six plants, other species also deserve careful study. It appears to us that the species with seven or more plants have rationality that is difficult to explain and some secrets that are yet to be deciphered. On the other hand, modern good praxis rules require the identification of all the plants in medical species. An increase in plants in the mixture requires advanced techniques for quality control. Notably, two medical species approved for use in officinal medicine include 7 and 12 plants. The efficacy of these species was investigated in vivo. However, all the activities were proved using only one model of alloxan-induced diabetes. Clinical trials were completed in small groups, and several details are not indicated in the reports. According to modern regulatory rules, additional pharmacological experiments and clinical trials are required for more detailed investigations of the mechanisms of action and the confirmation of efficacy. We believe that the scientifically based utilization of rich plant resources and knowledge of Russian herbal medicine can significantly contribute to the local economy as well as to the sectors seeking natural healing products.